19. On or about May 2, 2016, the Respondent's manager sent her for a Fitness for
Duty Evaluation. The Director noted that the evaluation was based on the
Respondent's disappearance from work, and complaints from other employees.

20. The Respondent's urine toxicology screen tested positive for naloxone (generic
name for Narcan), fentanyl and buprenorphine (generic name for Suboxone).

21. On or about May 3, 2016, the Director conducted an investigation, and
determined that “large volumes” of “drugs” had been missing from ICU units at Hospital
Aon six separate dates in April 2016 in which the Respondent had been on duty.

22. As a result of the Respondent's conduct, Hospital A terminated her from
employment.

INVESTIGATIVE FINDINGS BY BOARD STAFF

September 13, 2016 Interview of Respondent

23. On September 13, 2016, Board staff interviewed the Respondent under oath.

24. The Respondent described the July 2015 incident at Hospital A as taking place
during her shift at approximately 3:00 a.m. to 4:00 a.m. She was assigned to a trauma
unit that night, and had ingested oxycodone, morphine, and had placed a fentanyl
patch. She was not being prescribed the fentanyl any longer, but used a patch she had
from a previous prescription, and reportedly had removed it before reporting for work.
25. According to the Respondent, her health condition during the beginning of 2016
necessitated that she was unable to perform her best at work, and often had to “call

”

out
